Young Bum Yoo

Young Bum Yoo

Auto-generated profile, based on publicly available information

Young Bum Yoo

Department of Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
SLSeung Eun Lee
Seung Eun Lee
HPHa Young Park
Ha Young Park
SLSo Dug Lim
So Dug Lim
HHHye Seung Han
Hye Seung Han
YYYoung Bum Yoo
Young Bum Yoo
WKWan Seop Kim
Wan Seop Kim
Lee SE, et al. J Breast Cancer. 2019 Nov;23:e37. https://doi.org/10.4048/jbc.2020.23.e37

15 March 2022 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
JPJin Hee Park
Jin Hee Park
HHHye Seung Han
Hye Seung Han
SLSo Dug Lim
So Dug Lim
WKWook Youn Kim
Wook Youn Kim
Kyoung Sik ParkKyoung Sik Park
Kyoung Sik Park
WKWan Seop Kim
Wan Seop Kim
Background: Triple-negative breast cancer (TNBC) has a relatively poor prognosis. Research has identified potential metabolic targets, including fatty acid metabolism, in TNBC. The absence of effective target therapies for TNBC led to exploration of the role of fatty acid synthetase (FASN) as a potential target for TNBC therapy. Here, we analyzed the expression of FASN, a representative lipid metabolism–related protein, and investigated the association between FASN expression and Ki-67 and the programmed death ligand 1 (PD-L1) biomarkers in TNBC.Methods: Immunohistochemical expression of FASN was analyzed in 166 patients with TNBC. For analytical purposes, patients with 0–1+ FASN staining were grouped as low-grade FASN and patients with 2–3+ FASN staining as high-grade FASN.Results: FASN expression was observed in 47.1% of TNBC patients. Low and high expression of FASN was identified in 75.9% and 24.1%, respectively, and no statistically significant difference was found in T category, N category, American Joint Committee on Cancer stage, or recurrence rate between the low and high-FASN expression groups. Ki-67 proliferation level was significantly different between the low and high-FASN expression groups. FASN expression was significantly related to Ki-67 as the level increased. There was no significant difference in PD-L1 positivity between the low- and high-FASN expression groups.Conclusions: We identified FASN expression in 166 TNBC patients. The Ki-67 proliferation index was positively correlated with FASN level, indicating higher proliferation activity as FASN increases. However, there was no statistical association with PD-L1 SP142, the currently FDA-approved assay, or FASN expression level.